Total Androgen Blockade

  • Fritz H. Schröder
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)


In most Western countries prostatic cancer is the second to third most frequent cause of cancer death in males. The death rate from this tumor has not changed throughout the years. This is mainly due to the fact that most prostatic carcinomas are diagnosed in a metastatic stage. Unfortunately, an effective, curative treatment of this disease is not known [1]. Endocrine management, which produces excellent palliation in 70-80% of all cases, which is associated with an objective response in 20-40% and a significant prolongation of the symptom-free interval, never, or almost never, leads to the cure of a patient. Due to the high incidence of competing causes of death, many patients die with, rather than of, their prostatic carcinoma. Some response rates obtained in recent prospective randomized trials are summarized in Table 1.


Prostatic Carcinoma Plasma Testosterone Adrenal Androgen Prostatic Acid Phosphatase LHRH Agonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Whitmore WF: The natural history of prostatic cancer. Cancer 1973 (32):1104–1112PubMedCrossRefGoogle Scholar
  2. 2.
    Smith PH, Pavone Macaluso M, Viggiano G, De Voogt HJ, Lardennois B, Robinson MRG, Richards B: EORTC protocols in prostatic cancer. In: Denis L, Murphy GP, Prout GR, Schröder FH (eds) Controlled Clinical Trials in Urologie Oncology. Raven Press, New York 1984 pp 107–111Google Scholar
  3. 3.
    Murphy GP, Slack NH and participants in the National Prostatic Cancer Project: Current status of the National Prostatic Cancer Project treatment protocols. In: Denis L, Murphy GP, Prout GR, Schröder FH (eds) Controlled Clinical Trials in Urologie Oncology. Raven Press, New York 1984 pp 119–134Google Scholar
  4. 4.
    Smith PH, Suciu S, Robinson MRG, Richards B, Bastable JRG, Glashan RW, Bouffioux C, Lardennois B, Williams RE, De Pauw M, Sylvester R: A comparison of the effect of Diethylstilbestrol with low dose estramustine phosphatase in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on the Treatment of Cancer. J Urol 1986 (136):619–623PubMedGoogle Scholar
  5. 5.
    Labrie F, Dupont A, Belanger A, Giguere M, Lacoursiere Y, Edmon J, Monfette G, Bergeron V: Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem 1985 (23):833–841PubMedCrossRefGoogle Scholar
  6. 6.
    Labrie F, Dupont A, Belanger A: Complete androgen blockade for the treatment of prostate cancer. In: DeVita Jr VT, Hellman S, Rosenberg SA (eds) Important Advances in Oncology 1985. JB Lippincott Company, Philadelphia 1985 pp 193–217Google Scholar
  7. 7.
    Romijn JC, Van Steenbrugge GJ, Blankenstein MA, Schröder FH: Animal models in prostatic cancer. In: Pavone- Macaluso M, Smith PH (eds) Cancer of the Prostate and Kidney. Plenum Press, New York and London 1983 pp 35–44Google Scholar
  8. 8.
    Matsumoto K, Sato B, Kitamura Y: Roles of androgen and its receptors in mouse mammary tumor. In: Leung S (ed) Hormonal Regulation of Mammary Tumors. Vol IB. Eden Press, Montreal 1982 pp 216–244Google Scholar
  9. 9.
    Isaacs JT, Heston WDW, Weissman RM, Coffey DS: Animal models of the hormone-sensitive and insensitive prostatic adenocarcinomas, Dunning R3327-H, R3327-HI and R3327-AT. Cancer Res 1978 (38):4353–4359PubMedGoogle Scholar
  10. 10.
    Noble RL: The development of prostatic adenocarcinoma in the NB rats following prolonged sex hormone administration. Cancer Res 1977 (17):1929Google Scholar
  11. 11.
    Van Steenbrugge GJ, Groen M, Romijn JC, Schröder FH: Biological effects of hormonal treatment regimens on a transplantable human prostatic tumor line (PC-82). J Urol 1984 (131):812–817PubMedGoogle Scholar
  12. 12.
    Labrie F, Veilleux R: A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells. The Prostate 1986 (8):293–300PubMedCrossRefGoogle Scholar
  13. 13.
    Van Steenbrugge GJ, Van Dongen JJW, Reuvers PJ, De Jong FH, Schröder FH: Transplantable human prostatic carcinoma (PC-82) in athymic nude mice: I. Hormone dependence and the concentration of androgens in plasma and tumor tissue. Submitted for publicationGoogle Scholar
  14. 14.
    Geller J, Albert J, Loza D, Geller S, Stoeltzing W, De La Vega D: DHT concentrations in human prostate cancer tissue. J Clin Endocrinol Metab 1978 (46):440PubMedCrossRefGoogle Scholar
  15. 15.
    Geller J, Albert JD, Nachtsheim DA, Loza D: Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol 1984 (132):693–696PubMedGoogle Scholar
  16. 16.
    Labrie F, Luthy I, Veilleux R, Simard J, Belanger A, Dupont A: New concepts on the androgen sensitivity of prostate cancer. In: Murphy GP (ed) Second International Symposium on Prostate Cancer. Alan R Liss, New York 1987 (in press)Google Scholar
  17. 17.
    Oesterling JE, Epstein JI, Walsh PC: The inability of adrenal androgens to stimulate the adult human prostate: an autopsy evaluation of men with hypogonadotropic hypogonadism and panhypopituitarism. J Urol 1986 (136):1030–1034PubMedGoogle Scholar
  18. 18.
    Brisset JM, Boccon-Gibod L, Botto H, Carney M, Cariou G, Duclos JM, Duval F, Gonties D, Jorest R, Lamy L, Le Due A, Moutin A, Petit M, Prawerman A, Richard F, Savatovsky I, Vallancien G: Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo. In: Khoury S, Murphy GP (eds) Cancer of the Prostate. Alan R Liss, New York 1987 (in press)Google Scholar
  19. 19.
    Navratil H: Double-blind study of anandron versus placebo in stage D2 prostate cancer patients receiving Buserelin. Results on 49 cases from a multicenter study. In: Khoury S, Murphy GP (eds) Cancer of the Prostate. Alan R Liss, New York 1987 (in press)Google Scholar
  20. 20.
    Shearer RJ, Hendry WF, Sommerville IF, Fergusson JD: Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer. Br J Urol 1973 (45):668–677PubMedCrossRefGoogle Scholar
  21. 21.
    Robinson MRG, Hetherington J: The EORTC studies: is there an optimal endocrine management for M1 prostatic cancer? World J Urol 1986 (4):1–5CrossRefGoogle Scholar
  22. 22.
    Poyet P, Labrie F: Comparison of the antiandrogen/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol Cell Endocrinol 1985 (42):283–288PubMedCrossRefGoogle Scholar
  23. 23.
    Knuth UA, Hano R, Nieschlag E: Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men. J Clin Endocrinol Metab 1984 (59):963–969PubMedCrossRefGoogle Scholar
  24. 24.
    Habenicht UF, Witthaus E, Neumann F: Antiandrogene und LH-RH-Agonisten; Endokrinologie in der Initialphase ihrer Anwendung. Akt Urol 1986 (17):10–16CrossRefGoogle Scholar
  25. 25.
    Huang JK, Bartsch W, Voigt KD: Interactions of an anti-androgen (cyproterone acetate) with the androgen receptor system and its biological action in the rat ventral prostrate. Acta Endocrinol 1985 (109):569–576PubMedGoogle Scholar
  26. 26.
    Klijn JGM, De Voogt HJ, Schröder FH, De Jong FH: Combined treatment with Buserelin and Cyproterone acetate in metastatic prostatic carcinoma. Lancet 1985 (31):493Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • Fritz H. Schröder
    • 1
  1. 1.Department of UrologyErasmus UniversityRotterdamThe Netherlands

Personalised recommendations